🧫 Experiment Protocol
ValidationFCGRTIgG1-Fc humanized hFCGRT transgenic miceproposed
This experiment evaluated the pharmacokinetic behavior of administered humanized monoclonal antibodies in the newly created IgG1-Fc humanized mice compared to control conditions. The study demonstrated that endogenous chimeric IgG1 produced by the engineered mice significantly dampened the serum half-life of administered humanized mAbs in an hFCGRT-dependent manner. This competitive effect was designed to more accurately model the human physiological condition where endogenous human IgG competes with therapeutic antibodies for FcRn binding, providing a more translationally relevant preclinical model for human IgG-based biologics development.
PRIMARY OUTCOME
Serum half-life of administered humanized monoclonal antibodies
EXPECTED OUTCOMES
Reduced serum half-life of administered humanized mAbs due to competition with endogenous chimeric IgG1
SUCCESS CRITERIA
Significant dampening of humanized mAb serum half-life in an hFCGRT-dependent manner
PROTOCOL
Administration of humanized mAbs to IgG1-Fc humanized mice followed by pharmacokinetic analysis and comparison to control conditions